{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:30:15Z","timestamp":1789695015926,"version":"4.0.1"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11060-025-04942-0","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T10:57:45Z","timestamp":1739530665000},"page":"503-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeted treatment for craniopharyngioma"],"prefix":"10.1007","volume":"172","author":[{"given":"Natalie E.","family":"Stec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Fred G.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"4942_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"4942_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00006123-200002000-00007","volume":"46","author":"J Duff","year":"2000","unstructured":"Duff J et al (2000) Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 46:291\u2013302 discussion 302\u2013\u2009295. https:\/\/doi.org\/10.1097\/00006123-200002000-00007","journal-title":"Neurosurgery"},{"key":"4942_CR3","doi-asserted-by":"publisher","first-page":"e32112","DOI":"10.1016\/j.heliyon.2024.e32112","volume":"10","author":"MN Alboqami","year":"2024","unstructured":"Alboqami MN et al (2024) A comprehensive review of the clinical presentation, radiological findings, management, and future perspective. Heliyon 10:e32112. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32112. Craniopharyngioma","journal-title":"Heliyon"},{"key":"4942_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3171\/2018.5.Jns18153","volume":"131","author":"JM Pascual","year":"2019","unstructured":"Pascual JM, Prieto R, Barrios L (2019) Harvey Cushing\u2019s craniopharyngioma treatment: part 1. Identification and clinicopathological characterization of this challenging pituitary tumor. J Neurosurg 131:949\u2013963. https:\/\/doi.org\/10.3171\/2018.5.Jns18153","journal-title":"J Neurosurg"},{"key":"4942_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3171\/2018.10.Jns181557","volume":"132","author":"H Giese","year":"2020","unstructured":"Giese H, Haenig B, Haenig A, Unterberg A, Zweckberger K (2020) Neurological and neuropsychological outcome after resection of craniopharyngiomas. J Neurosurg 132:1425\u20131434. https:\/\/doi.org\/10.3171\/2018.10.Jns181557","journal-title":"J Neurosurg"},{"key":"4942_CR6","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/neuonc\/nos142","volume":"14","author":"BE Zacharia","year":"2012","unstructured":"Zacharia BE et al (2012) Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro Oncol 14:1070\u20131078. https:\/\/doi.org\/10.1093\/neuonc\/nos142","journal-title":"Neuro Oncol"},{"key":"4942_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11102-021-01127-6","volume":"24","author":"AA Momin","year":"2021","unstructured":"Momin AA et al (2021) Descriptive epidemiology of craniopharyngiomas in the United States. Pituitary 24:517\u2013522. https:\/\/doi.org\/10.1007\/s11102-021-01127-6","journal-title":"Pituitary"},{"key":"4942_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-005-1004-x","volume":"109","author":"R Buslei","year":"2005","unstructured":"Buslei R et al (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109:589\u2013597. https:\/\/doi.org\/10.1007\/s00401-005-1004-x","journal-title":"Acta Neuropathol"},{"key":"4942_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1750-3639.2008.00180.x","volume":"19","author":"A H\u00f6lsken","year":"2009","unstructured":"H\u00f6lsken A et al (2009) Target gene activation of the wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas. Brain Pathol 19:357\u2013364. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00180.x","journal-title":"Brain Pathol"},{"key":"4942_CR10","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/s0002-9440(10)64477-x","volume":"161","author":"S Sekine","year":"2002","unstructured":"Sekine S et al (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997\u20132001. https:\/\/doi.org\/10.1016\/s0002-9440(10)64477-x","journal-title":"Am J Pathol"},{"key":"4942_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK et al (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161\u2013165. https:\/\/doi.org\/10.1038\/ng.2868","journal-title":"Nat Genet"},{"key":"4942_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/jnen\/nlw116","volume":"76","author":"T Goschzik","year":"2017","unstructured":"Goschzik T et al (2017) Genomic alterations of Adamantinomatous and Papillary Craniopharyngioma. J Neuropathol Exp Neurol 76:126\u2013134. https:\/\/doi.org\/10.1093\/jnen\/nlw116","journal-title":"J Neuropathol Exp Neurol"},{"key":"4942_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","volume":"4","author":"A H\u00f6lsken","year":"2016","unstructured":"H\u00f6lsken A et al (2016) Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 4:20. https:\/\/doi.org\/10.1186\/s40478-016-0287-6","journal-title":"Acta Neuropathol Commun"},{"key":"4942_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3171\/2021.5.Jns202011","volume":"136","author":"SS Godil","year":"2022","unstructured":"Godil SS et al (2022) Long-term tumor control after endoscopic endonasal resection of craniopharyngiomas: comparison of gross-total resection versus subtotal resection with radiation therapy. J Neurosurg 136:1347\u20131355. https:\/\/doi.org\/10.3171\/2021.5.Jns202011","journal-title":"J Neurosurg"},{"key":"4942_CR15","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3171\/2023.3.Jns222607","volume":"139","author":"EJ Bobeff","year":"2023","unstructured":"Bobeff EJ et al (2023) Predictors of extent of resection and recurrence following endoscopic endonasal resection of craniopharyngioma. J Neurosurg 139:1235\u20131246. https:\/\/doi.org\/10.3171\/2023.3.Jns222607","journal-title":"J Neurosurg"},{"key":"4942_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3171\/2009.7.Peds09215","volume":"5","author":"RE Elliott","year":"2010","unstructured":"Elliott RE et al (2010) Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. J Neurosurg Pediatr 5:30\u201348. https:\/\/doi.org\/10.3171\/2009.7.Peds09215","journal-title":"J Neurosurg Pediatr"},{"key":"4942_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11060-012-0806-7","volume":"108","author":"A Schoenfeld","year":"2012","unstructured":"Schoenfeld A et al (2012) The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol 108:133\u2013139. https:\/\/doi.org\/10.1007\/s11060-012-0806-7","journal-title":"J Neurooncol"},{"key":"4942_CR18","doi-asserted-by":"publisher","first-page":"e656","DOI":"10.1016\/j.wneu.2019.03.239","volume":"127","author":"OO Akinduro","year":"2019","unstructured":"Akinduro OO et al (2019) Endocrine and visual outcomes following gross total resection and Subtotal Resection of Adult Craniopharyngioma: systematic review and Meta-analysis. World Neurosurg 127:e656\u2013e668. https:\/\/doi.org\/10.1016\/j.wneu.2019.03.239","journal-title":"World Neurosurg"},{"issue":"Suppl 1","key":"4942_CR19","first-page":"399","volume":"19","author":"G Scarzello","year":"2006","unstructured":"Scarzello G et al (2006) Acute and late morbidity after limited resection and focal radiation therapy in craniopharyngiomas. J Pediatr Endocrinol Metab 19(Suppl 1):399\u2013405","journal-title":"J Pediatr Endocrinol Metab"},{"key":"4942_CR20","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2010.1.Focus09307","volume":"28","author":"I Yang","year":"2010","unstructured":"Yang I et al (2010) Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 28:E5. https:\/\/doi.org\/10.3171\/2010.1.Focus09307","journal-title":"Neurosurg Focus"},{"key":"4942_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/neuros\/nyx570","volume":"83","author":"C Dandurand","year":"2018","unstructured":"Dandurand C, Sepehry AA, Asadi Lari MH, Akagami R, Gooderham P (2018) Adult craniopharyngioma: Case Series, systematic review, and Meta-Analysis. Neurosurgery 83:631\u2013641. https:\/\/doi.org\/10.1093\/neuros\/nyx570","journal-title":"Neurosurgery"},{"key":"4942_CR22","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.1016\/j.wneu.2024.04.177","volume":"187","author":"SJ Poiset","year":"2024","unstructured":"Poiset SJ et al (2024) Long-term outcomes of surgery and Radiation Treatment for adult patients with Craniopharyngioma. World Neurosurg 187:e852\u2013e859. https:\/\/doi.org\/10.1016\/j.wneu.2024.04.177","journal-title":"World Neurosurg"},{"key":"4942_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jss.2018.01.029","volume":"226","author":"G Wang","year":"2018","unstructured":"Wang G, Zhang X, Feng M, Guo F (2018) Comparing survival outcomes of gross total resection and subtotal resection with radiotherapy for craniopharyngioma: a meta-analysis. J Surg Res 226:131\u2013139. https:\/\/doi.org\/10.1016\/j.jss.2018.01.029","journal-title":"J Surg Res"},{"key":"4942_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.wneu.2017.08.058","volume":"108","author":"VS Patel","year":"2017","unstructured":"Patel VS et al (2017) Outcomes after endoscopic endonasal resection of Craniopharyngiomas in the Pediatric Population. World Neurosurg 108:6\u201314. https:\/\/doi.org\/10.1016\/j.wneu.2017.08.058","journal-title":"World Neurosurg"},{"key":"4942_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000515347","volume":"93","author":"A Bereket","year":"2020","unstructured":"Bereket A (2020) Postoperative and long-term endocrinologic complications of Craniopharyngioma. Horm Res Paediatr 93:497\u2013509. https:\/\/doi.org\/10.1159\/000515347","journal-title":"Horm Res Paediatr"},{"key":"4942_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3171\/2023.10.Peds23293","volume":"33","author":"M Caklili","year":"2024","unstructured":"Caklili M et al (2024) Surgical outcomes and follow-up results of 53 pediatric craniopharyngioma cases: a single-center study. J Neurosurg Pediatr 33:223\u2013235. https:\/\/doi.org\/10.3171\/2023.10.Peds23293","journal-title":"J Neurosurg Pediatr"},{"key":"4942_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3171\/2023.3.Jns222302","volume":"139","author":"S Sadhasivam","year":"2023","unstructured":"Sadhasivam S, Menon G, Abraham M, Arora RK, Nair SN (2023) The influence of tumor topography on the surgical outcome of craniopharyngiomas. J Neurosurg 139:1247\u20131257. https:\/\/doi.org\/10.3171\/2023.3.Jns222302","journal-title":"J Neurosurg"},{"key":"4942_CR28","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1210\/jc.2012-3928","volume":"98","author":"E Elowe-Gruau","year":"2013","unstructured":"Elowe-Gruau E et al (2013) Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 98:2376\u20132382. https:\/\/doi.org\/10.1210\/jc.2012-3928","journal-title":"J Clin Endocrinol Metab"},{"key":"4942_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.wneu.2017.01.005","volume":"100","author":"S Yano","year":"2017","unstructured":"Yano S, Hide T, Shinojima N (2017) Surgical outcomes of Endoscopic Endonasal Skull Base surgery of Craniopharyngiomas Evaluated according to the degree of hypothalamic extension. World Neurosurg 100:288\u2013296. https:\/\/doi.org\/10.1016\/j.wneu.2017.01.005","journal-title":"World Neurosurg"},{"key":"4942_CR30","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3171\/2013.6.Jns122259","volume":"119","author":"M Koutourousiou","year":"2013","unstructured":"Koutourousiou M et al (2013) Endoscopic endonasal surgery for craniopharyngiomas: surgical outcome in 64 patients. J Neurosurg 119:1194\u20131207. https:\/\/doi.org\/10.3171\/2013.6.Jns122259","journal-title":"J Neurosurg"},{"key":"4942_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/0284186x.2012.685525","volume":"52","author":"L Masson-Cote","year":"2013","unstructured":"Masson-Cote L et al (2013) Long-term outcomes for adult craniopharyngioma following radiation therapy. Acta Oncol 52:153\u2013158. https:\/\/doi.org\/10.3109\/0284186x.2012.685525","journal-title":"Acta Oncol"},{"key":"4942_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2014.01.019","volume":"88","author":"AC Lo","year":"2014","unstructured":"Lo AC et al (2014) Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys 88:1011\u20131018. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4942_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ijrobp.2021.02.045","volume":"110","author":"RB Jimenez","year":"2021","unstructured":"Jimenez RB et al (2021) Proton Radiation Therapy for Pediatric Craniopharyngioma. Int J Radiat Oncol Biol Phys 110:1480\u20131487. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.02.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4942_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/pbc.25889","volume":"63","author":"AC Lo","year":"2016","unstructured":"Lo AC et al (2016) A cross-sectional cohort study of Cerebrovascular Disease and Late effects after Radiation Therapy for Craniopharyngioma. Pediatr Blood Cancer 63:786\u2013793. https:\/\/doi.org\/10.1002\/pbc.25889","journal-title":"Pediatr Blood Cancer"},{"key":"4942_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/jc.2014-3525","volume":"100","author":"DS Olsson","year":"2015","unstructured":"Olsson DS, Andersson E, Bryngelsson I-L, Nilsson AG, Johannsson G (2015) Excess mortality and morbidity in patients with Craniopharyngioma, especially in patients with Childhood Onset: a Population-based study in Sweden. J Clin Endocrinol Metabolism 100:467\u2013474. https:\/\/doi.org\/10.1210\/jc.2014-3525","journal-title":"J Clin Endocrinol Metabolism"},{"key":"4942_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11060-022-03983-z","volume":"157","author":"MS Rutenberg","year":"2022","unstructured":"Rutenberg MS et al (2022) Disease Control after Radiotherapy for Adult Craniopharyngioma: clinical outcomes from a large single-Institution Series. J Neurooncol 157:425\u2013433. https:\/\/doi.org\/10.1007\/s11060-022-03983-z","journal-title":"J Neurooncol"},{"key":"4942_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ijrobp.2022.09.061","volume":"115","author":"TE Merchant","year":"2023","unstructured":"Merchant TE et al (2023) Pediatric Craniopharyngioma: the Effect of Visual deficits and hormone deficiencies on long-term cognitive outcomes after Conformal Photon Radiation Therapy. Int J Radiat Oncol Biol Phys 115:581\u2013591. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.061","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4942_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pbc.21787","volume":"52","author":"AK Liu","year":"2009","unstructured":"Liu AK et al (2009) Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer 52:227\u2013230. https:\/\/doi.org\/10.1002\/pbc.21787","journal-title":"Pediatr Blood Cancer"},{"key":"4942_CR39","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/neuonc\/noac124","volume":"24","author":"DY Edmonston","year":"2022","unstructured":"Edmonston DY et al (2022) Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocol. Neuro Oncol 24:2200\u20132209. https:\/\/doi.org\/10.1093\/neuonc\/noac124","journal-title":"Neuro Oncol"},{"key":"4942_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.wneu.2022.05.038","volume":"164","author":"M Castle-Kirszbaum","year":"2022","unstructured":"Castle-Kirszbaum M, Shi MDY, Goldschlager T (2022) Quality of life in Craniopharyngioma: a systematic review. World Neurosurg 164:424\u2013435e422. https:\/\/doi.org\/10.1016\/j.wneu.2022.05.038","journal-title":"World Neurosurg"},{"key":"4942_CR41","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2010.1.Focus09310","volume":"28","author":"S Cavalheiro","year":"2010","unstructured":"Cavalheiro S et al (2010) Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus 28:E12. https:\/\/doi.org\/10.3171\/2010.1.Focus09310","journal-title":"Neurosurg Focus"},{"key":"4942_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-012-0902-8","volume":"109","author":"P Kickingereder","year":"2012","unstructured":"Kickingereder P et al (2012) Intracavitary brachytherapy using stereotactically applied phosphorus-32 colloid for treatment of cystic craniopharyngiomas in 53 patients. J Neurooncol 109:365\u2013374. https:\/\/doi.org\/10.1007\/s11060-012-0902-8","journal-title":"J Neurooncol"},{"key":"4942_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1227\/NEU.0b013e31826d5c31","volume":"71","author":"W Liu","year":"2012","unstructured":"Liu W et al (2012) Intracystic bleomycin for cystic craniopharyngiomas in children (abridged republication of cochrane systematic review). Neurosurgery 71:909\u2013915. https:\/\/doi.org\/10.1227\/NEU.0b013e31826d5c31","journal-title":"Neurosurgery"},{"key":"4942_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000055955","volume":"33","author":"WJ Hader","year":"2000","unstructured":"Hader WJ, Steinbok P, Hukin J, Fryer C (2000) Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg 33:211\u2013218. https:\/\/doi.org\/10.1159\/000055955","journal-title":"Pediatr Neurosurg"},{"key":"4942_CR45","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1038\/sj.onc.1207785","volume":"23","author":"M Karasarides","year":"2004","unstructured":"Karasarides M et al (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292\u20136298. https:\/\/doi.org\/10.1038\/sj.onc.1207785","journal-title":"Oncogene"},{"key":"4942_CR46","doi-asserted-by":"publisher","unstructured":"Degirmenci U, Wang M, Hu J, Targeting Aberrant (2020) RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy. Cells 9. https:\/\/doi.org\/10.3390\/cells9010198","DOI":"10.3390\/cells9010198"},{"key":"4942_CR47","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/jco.23.00774","volume":"41","author":"GJ Riely","year":"2023","unstructured":"Riely GJ et al (2023) Phase II, open-label study of Encorafenib Plus Binimetinib in patients with BRAF(V600)-Mutant metastatic non-small-cell Lung Cancer. J Clin Oncol 41:3700\u20133711. https:\/\/doi.org\/10.1200\/jco.23.00774","journal-title":"J Clin Oncol"},{"key":"4942_CR48","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877\u20131888. https:\/\/doi.org\/10.1056\/NEJMoa1406037","journal-title":"N Engl J Med"},{"key":"4942_CR49","doi-asserted-by":"crossref","unstructured":"Kopetz, S.et al. Encorafenib, Binimetinib, and Cetuximab in <\u2009i\u2009>\u2009BRAF\u2009V600E\u2013Mutated Colorectal Cancer. New England Journal of Medicine381, 1632\u20131643 (2019). https:\/\/doi.org\/doi:10.1056\/NEJMoa1908075","DOI":"10.1056\/NEJMoa1908075"},{"key":"4942_CR50","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2021013658","volume":"141","author":"RJ Kreitman","year":"2023","unstructured":"Kreitman RJ et al (2023) Dabrafenib plus Trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood 141:996\u20131006. https:\/\/doi.org\/10.1182\/blood.2021013658","journal-title":"Blood"},{"key":"4942_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.Ccr-23-1503","volume":"30","author":"MI Barbato","year":"2024","unstructured":"Barbato MI et al (2024) FDA approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E mutation-positive low-Grade Glioma. Clin Cancer Res 30:263\u2013268. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1503","journal-title":"Clin Cancer Res"},{"key":"4942_CR52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387\u2013390. https:\/\/doi.org\/10.1038\/nature10662","journal-title":"Nature"},{"key":"4942_CR53","doi-asserted-by":"publisher","first-page":"e920957","DOI":"10.12659\/msm.920957","volume":"26","author":"Y Tian","year":"2020","unstructured":"Tian Y, Guo WA (2020) Review of the molecular pathways involved in resistance to BRAF inhibitors in patients with Advanced-Stage Melanoma. Med Sci Monit 26:e920957. https:\/\/doi.org\/10.12659\/msm.920957","journal-title":"Med Sci Monit"},{"key":"4942_CR54","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444\u2013451. https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4","journal-title":"Lancet"},{"key":"4942_CR55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N, Solit DB (2024) BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol 21:224\u2013247. https:\/\/doi.org\/10.1038\/s41571-023-00852-0","journal-title":"Nat Rev Clin Oncol"},{"key":"4942_CR56","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L et al (2019) Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4:e000491. https:\/\/doi.org\/10.1136\/esmoopen-2019-000491","journal-title":"ESMO Open"},{"key":"4942_CR57","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/cmr.0000000000000599","volume":"29","author":"AG Mackin","year":"2019","unstructured":"Mackin AG et al (2019) Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res 29:522\u2013526. https:\/\/doi.org\/10.1097\/cmr.0000000000000599","journal-title":"Melanoma Res"},{"key":"4942_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107\u2013114. https:\/\/doi.org\/10.1056\/NEJMoa1203421","journal-title":"N Engl J Med"},{"key":"4942_CR59","doi-asserted-by":"publisher","unstructured":"Garutti M et al (2022) BRAF and MEK inhibitors and their toxicities: a Meta-analysis. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15010141","DOI":"10.3390\/cancers15010141"},{"key":"4942_CR60","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","volume":"24","author":"L Boussemart","year":"2013","unstructured":"Boussemart L et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691\u20131697. https:\/\/doi.org\/10.1093\/annonc\/mdt015","journal-title":"Ann Oncol"},{"key":"4942_CR61","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/bjc.2014.139","volume":"111","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Nagel TE, Stuart DD (2014) Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer 111:640\u2013645. https:\/\/doi.org\/10.1038\/bjc.2014.139","journal-title":"Br J Cancer"},{"key":"4942_CR62","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","volume":"71","author":"M Sanlorenzo","year":"2014","unstructured":"Sanlorenzo M et al (2014) Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol 71:1102\u20131109e1101. https:\/\/doi.org\/10.1016\/j.jaad.2014.09.002","journal-title":"J Am Acad Dermatol"},{"key":"4942_CR63","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","volume":"17","author":"M Banks","year":"2017","unstructured":"Banks M, Crowell K, Proctor A, Jensen BC (2017) Cardiovascular effects of the MEK inhibitor, Trametinib: a Case Report, Literature Review, and consideration of mechanism. Cardiovasc Toxicol 17:487\u2013493. https:\/\/doi.org\/10.1007\/s12012-017-9425-z","journal-title":"Cardiovasc Toxicol"},{"key":"4942_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fphys.2017.00041","volume":"8","author":"H Zhu","year":"2017","unstructured":"Zhu H et al (2017) Increased apoptosis in the Paraventricular Nucleus mediated by AT1R\/Ras\/ERK1\/2 signaling results in sympathetic hyperactivity and renovascular hypertension in rats after kidney Injury. Front Physiol 8:41. https:\/\/doi.org\/10.3389\/fphys.2017.00041","journal-title":"Front Physiol"},{"key":"4942_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/14740338.2015.986092","volume":"14","author":"G Bronte","year":"2015","unstructured":"Bronte G et al (2015) Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opin Drug Saf 14:253\u2013267. https:\/\/doi.org\/10.1517\/14740338.2015.986092","journal-title":"Expert Opin Drug Saf"},{"key":"4942_CR66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/circulationaha.111.087155","volume":"126","author":"M Totzeck","year":"2012","unstructured":"Totzeck M et al (2012) Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation 126:325\u2013334. https:\/\/doi.org\/10.1161\/circulationaha.111.087155","journal-title":"Circulation"},{"key":"4942_CR67","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1002\/cam4.3938","volume":"10","author":"A Guha","year":"2021","unstructured":"Guha A et al (2021) Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries. Cancer Med 10:3862\u20133872. https:\/\/doi.org\/10.1002\/cam4.3938","journal-title":"Cancer Med"},{"key":"4942_CR68","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI et al (2019) Cardiovascular adverse events Associated with BRAF and MEK inhibitors: a systematic review and Meta-analysis. JAMA Netw Open 2:e198890. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.8890","journal-title":"JAMA Netw Open"},{"key":"4942_CR69","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","volume":"128","author":"C Mettler","year":"2021","unstructured":"Mettler C et al (2021) Ocular Safety Profile of BRAF and MEK inhibitors: data from the World Health Organization Pharmacovigilance Database. Ophthalmology 128:1748\u20131755. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.008","journal-title":"Ophthalmology"},{"key":"4942_CR70","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/iae.0000000000002451","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","unstructured":"M\u00e9ndez-Mart\u00ednez S et al (2019) OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina 39:1435\u20131450. https:\/\/doi.org\/10.1097\/iae.0000000000002451","journal-title":"Retina"},{"key":"4942_CR71","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","volume":"65","author":"U Urner-Bloch","year":"2016","unstructured":"Urner-Bloch U et al (2016) MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer 65:130\u2013138. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.018","journal-title":"Eur J Cancer"},{"key":"4942_CR72","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.ajo.2015.07.035","volume":"160","author":"A Niro","year":"2015","unstructured":"Niro A et al (2015) Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase kinase inhibitors: a Case Series. Am J Ophthalmol 160:959\u2013967e951. https:\/\/doi.org\/10.1016\/j.ajo.2015.07.035","journal-title":"Am J Ophthalmol"},{"key":"4942_CR73","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK et al (2023) BRAF-MEK inhibition in newly diagnosed Papillary Craniopharyngiomas. N Engl J Med 389:118\u2013126. https:\/\/doi.org\/10.1056\/NEJMoa2213329","journal-title":"N Engl J Med"},{"key":"4942_CR74","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12885-015-1754-3","volume":"15","author":"V Giraud","year":"2015","unstructured":"Giraud V et al (2015) Relapsing pneumonitis due to two distinct inhibitors of the MAPK\/ERK pathway: report of a case. BMC Cancer 15:732. https:\/\/doi.org\/10.1186\/s12885-015-1754-3","journal-title":"BMC Cancer"},{"key":"4942_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","volume":"109","author":"C Robert","year":"2019","unstructured":"Robert C et al (2019) Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K-mutant advanced or metastatic melanoma. Eur J Cancer 109:61\u201369. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.015","journal-title":"Eur J Cancer"},{"key":"4942_CR76","doi-asserted-by":"publisher","unstructured":"Meirson T, Asher N, Bomze D, Markel G (2020) Safety of BRAF\u2009+\u2009MEK inhibitor combinations: severe adverse event evaluation. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12061650","DOI":"10.3390\/cancers12061650"},{"key":"4942_CR77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.ajkd.2016.12.013","volume":"70","author":"L Perico","year":"2017","unstructured":"Perico L et al (2017) BRAF Signaling Pathway Inhibition, Podocyte Injury, and nephrotic syndrome. Am J Kidney Dis 70:145\u2013150. https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.013","journal-title":"Am J Kidney Dis"},{"key":"4942_CR78","doi-asserted-by":"publisher","first-page":"e7196","DOI":"10.1097\/md.0000000000007196","volume":"96","author":"M Maanaoui","year":"2017","unstructured":"Maanaoui M et al (2017) Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report. Med (Baltim) 96:e7196. https:\/\/doi.org\/10.1097\/md.0000000000007196","journal-title":"Med (Baltim)"},{"key":"4942_CR79","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/cad.0000000000001106","volume":"32","author":"A Sanagawa","year":"2021","unstructured":"Sanagawa A et al (2021) BRAF\/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. Anticancer Drugs 32:1076\u20131083. https:\/\/doi.org\/10.1097\/cad.0000000000001106","journal-title":"Anticancer Drugs"},{"key":"4942_CR80","doi-asserted-by":"publisher","unstructured":"Brastianos PK et al (2016) Dramatic response of BRAF V600E Mutant Papillary Craniopharyngioma to targeted therapy. J Natl Cancer Inst 108. https:\/\/doi.org\/10.1093\/jnci\/djv310","DOI":"10.1093\/jnci\/djv310"},{"key":"4942_CR81","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","volume":"19","author":"SJ Aylwin","year":"2016","unstructured":"Aylwin SJ, Bodi I, Beaney R (2016) Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19:544\u2013546. https:\/\/doi.org\/10.1007\/s11102-015-0663-4","journal-title":"Pituitary"},{"key":"4942_CR82","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","volume":"159","author":"E Rostami","year":"2017","unstructured":"Rostami E et al (2017) Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien) 159:2217\u20132221. https:\/\/doi.org\/10.1007\/s00701-017-3311-0","journal-title":"Acta Neurochir (Wien)"},{"key":"4942_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/cns-2016-0034","volume":"6","author":"A Roque","year":"2017","unstructured":"Roque A, Odia Y (2017) BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol 6:95\u201399. https:\/\/doi.org\/10.2217\/cns-2016-0034","journal-title":"CNS Oncol"},{"key":"4942_CR84","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3171\/2017.11.Jns172373","volume":"130","author":"BT Himes","year":"2019","unstructured":"Himes BT et al (2019) Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg 130:1299\u20131303. https:\/\/doi.org\/10.3171\/2017.11.Jns172373","journal-title":"J Neurosurg"},{"key":"4942_CR85","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3171\/2019.8.Jns19643","volume":"133","author":"A Bernstein","year":"2020","unstructured":"Bernstein A et al (2020) Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg 133:1704\u20131709. https:\/\/doi.org\/10.3171\/2019.8.Jns19643","journal-title":"J Neurosurg"},{"key":"4942_CR86","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.18632\/oncotarget.27203","volume":"10","author":"M Rao","year":"2019","unstructured":"Rao M, Bhattacharjee M, Shepard S, Hsu S (2019) Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget 10:6038\u20136042. https:\/\/doi.org\/10.18632\/oncotarget.27203","journal-title":"Oncotarget"},{"key":"4942_CR87","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","volume":"18","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G (2020) Successful use of BRAF\/MEK inhibitors as a Neoadjuvant Approach in the definitive treatment of Papillary Craniopharyngioma. J Natl Compr Canc Netw 18:1590\u20131595. https:\/\/doi.org\/10.6004\/jnccn.2020.7624","journal-title":"J Natl Compr Canc Netw"},{"key":"4942_CR88","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1212\/WNL.94.15_supplement.867","volume":"94","author":"M Gopal","year":"2020","unstructured":"Gopal M, Thakur G, Puduvalli V (2020) Initial presentation of Papillary Craniopharyngioma with BRAF Mutation Treated with adjuvant chemotherapy (867). Neurology 94:867. https:\/\/doi.org\/10.1212\/WNL.94.15_supplement.867","journal-title":"Neurology"},{"key":"4942_CR89","doi-asserted-by":"publisher","first-page":"vdaa141","DOI":"10.1093\/noajnl\/vdaa141","volume":"2","author":"AL Di Stefano","year":"2020","unstructured":"Di Stefano AL et al (2020) Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neurooncol Adv 2:vdaa141. https:\/\/doi.org\/10.1093\/noajnl\/vdaa141","journal-title":"Neurooncol Adv"},{"key":"4942_CR90","doi-asserted-by":"publisher","first-page":"bvab043","DOI":"10.1210\/jendso\/bvab043","volume":"5","author":"CL Chik","year":"2021","unstructured":"Chik CL, van Landeghem FKH, Easaw JC, Mehta V (2021) Aggressive childhood-onset Papillary Craniopharyngioma Managed with Vemurafenib, a BRAF inhibitor. J Endocr Soc 5:bvab043. https:\/\/doi.org\/10.1210\/jendso\/bvab043","journal-title":"J Endocr Soc"},{"key":"4942_CR91","doi-asserted-by":"publisher","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","volume":"13","author":"F Calvanese","year":"2022","unstructured":"Calvanese F et al (2022) Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult Papillary craniopharyngiomas: a New Treatment paradigm. Front Endocrinol (Lausanne) 13:882381. https:\/\/doi.org\/10.3389\/fendo.2022.882381","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4942_CR92","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jcpt.13600","volume":"47","author":"PE Nussbaum","year":"2022","unstructured":"Nussbaum PE et al (2022) Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: a potential treatment paradigm shift. J Clin Pharm Ther 47:826\u2013831. https:\/\/doi.org\/10.1111\/jcpt.13600","journal-title":"J Clin Pharm Ther"},{"key":"4942_CR93","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.wneu.2023.08.137","volume":"180","author":"ZP Wu","year":"2023","unstructured":"Wu ZP et al (2023) Case Report: successful use of BRAF\/MEK inhibitors in aggressive BRAF-mutant Craniopharyngioma. World Neurosurg 180:e117\u2013e126. https:\/\/doi.org\/10.1016\/j.wneu.2023.08.137","journal-title":"World Neurosurg"},{"key":"4942_CR94","doi-asserted-by":"publisher","first-page":"Cns106","DOI":"10.2217\/cns-2023-0018","volume":"13","author":"N Yu","year":"2024","unstructured":"Yu N et al (2024) Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review. CNS Oncol 13:Cns106. https:\/\/doi.org\/10.2217\/cns-2023-0018","journal-title":"CNS Oncol"},{"key":"4942_CR95","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00280-021-04234-0","volume":"87","author":"SU Butt","year":"2021","unstructured":"Butt SU et al (2021) BRAF\/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Cancer Chemother Pharmacol 87:437\u2013441. https:\/\/doi.org\/10.1007\/s00280-021-04234-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4942_CR96","doi-asserted-by":"publisher","first-page":"e40190","DOI":"10.7759\/cureus.40190","volume":"15","author":"SN Shah","year":"2023","unstructured":"Shah SN, Kaki PC, Shah SS, Shah SA (2023) Concurrent Radiation and targeted therapy for Papillary Craniopharyngioma: a Case Report. Cureus 15:e40190. https:\/\/doi.org\/10.7759\/cureus.40190","journal-title":"Cureus"},{"key":"4942_CR97","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ejendo\/lvae091","volume":"191","author":"D De Alcubierre","year":"2024","unstructured":"De Alcubierre D et al (2024) BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. Eur J Endocrinol 191:251\u2013261. https:\/\/doi.org\/10.1093\/ejendo\/lvae091","journal-title":"Eur J Endocrinol"},{"key":"4942_CR98","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.32197","volume":"125","author":"TA Juratli","year":"2019","unstructured":"Juratli TA et al (2019) Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125:2910\u20132914. https:\/\/doi.org\/10.1002\/cncr.32197","journal-title":"Cancer"},{"key":"4942_CR99","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","volume":"26","author":"AL Lin","year":"2023","unstructured":"Lin AL, Tabar V, Young RJ, Geer EB (2023) Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituitary 26:482\u2013487. https:\/\/doi.org\/10.1007\/s11102-023-01339-y","journal-title":"Pituitary"},{"key":"4942_CR100","doi-asserted-by":"publisher","unstructured":"Cossu G et al (2024) Update on neoadjuvant and adjuvant BRAF inhibitors in Papillary Craniopharyngioma: a systematic review. Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16203479","DOI":"10.3390\/cancers16203479"},{"key":"4942_CR101","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/s1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D et al (2016) Dabrafenib plus Trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984\u2013993. https:\/\/doi.org\/10.1016\/s1470-2045(16)30146-2","journal-title":"Lancet Oncol"},{"key":"4942_CR102","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/s1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D et al (2017) Dabrafenib plus Trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18:1307\u20131316. https:\/\/doi.org\/10.1016\/s1470-2045(17)30679-4","journal-title":"Lancet Oncol"},{"key":"4942_CR103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3171\/2017.4.Jns163113","volume":"129","author":"Q Yue","year":"2018","unstructured":"Yue Q et al (2018) Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. J Neurosurg 129:27\u201334. https:\/\/doi.org\/10.3171\/2017.4.Jns163113","journal-title":"J Neurosurg"},{"key":"4942_CR104","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1007\/s10143-022-01848-7","volume":"45","author":"JM Pascual","year":"2022","unstructured":"Pascual JM, Prieto R, Carrasco R, Barrios L (2022) Duct-like diverticulum at the base of third ventricle tumors: a morphological signature diagnostic of papillary craniopharyngioma. Neurosurg Rev 45:3361\u20133379. https:\/\/doi.org\/10.1007\/s10143-022-01848-7","journal-title":"Neurosurg Rev"},{"key":"4942_CR105","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/neuros\/nyy569","volume":"85","author":"S Fujio","year":"2019","unstructured":"Fujio S et al (2019) A clinical rule for preoperative prediction of BRAF Mutation Status in Craniopharyngiomas. Neurosurgery 85:204\u2013210. https:\/\/doi.org\/10.1093\/neuros\/nyy569","journal-title":"Neurosurgery"},{"key":"4942_CR106","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jmri.27761","volume":"54","author":"ZS Huang","year":"2021","unstructured":"Huang ZS et al (2021) Machine learning-based Multiparametric magnetic resonance imaging Radiomic Model for discrimination of pathological subtypes of Craniopharyngioma. J Magn Reson Imaging 54:1541\u20131550. https:\/\/doi.org\/10.1002\/jmri.27761","journal-title":"J Magn Reson Imaging"},{"key":"4942_CR107","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/1078-0432.Ccr-17-2157","volume":"23","author":"A Jimeno","year":"2017","unstructured":"Jimeno A et al (2017) A first-in-human phase I study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy receptor for wnt ligands, in patients with Advanced Solid tumors. Clin Cancer Res 23:7490\u20137497. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2157","journal-title":"Clin Cancer Res"},{"key":"4942_CR108","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1158\/1078-0432.Ccr-20-0489","volume":"26","author":"E Dotan","year":"2020","unstructured":"Dotan E et al (2020) Phase ib study of wnt inhibitor ipafricept with Gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic Cancer. Clin Cancer Res 26:5348\u20135357. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0489","journal-title":"Clin Cancer Res"},{"key":"4942_CR109","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ygyno.2019.04.001","volume":"154","author":"KN Moore","year":"2019","unstructured":"Moore KN et al (2019) A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 154:294\u2013301. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.001","journal-title":"Gynecol Oncol"},{"key":"4942_CR110","doi-asserted-by":"publisher","first-page":"e1700090","DOI":"10.1126\/sciadv.1700090","volume":"3","author":"MM Fischer","year":"2017","unstructured":"Fischer MM et al (2017) WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv 3:e1700090. https:\/\/doi.org\/10.1126\/sciadv.1700090","journal-title":"Sci Adv"},{"key":"4942_CR111","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/jco.2013.31.15_suppl.2540","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith DC et al (2013) First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. J Clin Oncol 31:2540\u20132540. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.2540","journal-title":"J Clin Oncol"},{"key":"4942_CR112","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond JR et al (2020) Phase ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat 184:53\u201362. https:\/\/doi.org\/10.1007\/s10549-020-05817-w","journal-title":"Breast Cancer Res Treat"},{"key":"4942_CR113","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10637-019-00824-1","volume":"38","author":"SL Davis","year":"2020","unstructured":"Davis SL et al (2020) A phase 1b dose escalation study of wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs 38:821\u2013830. https:\/\/doi.org\/10.1007\/s10637-019-00824-1","journal-title":"Invest New Drugs"},{"key":"4942_CR114","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1158\/1078-0432.Ccr-20-1310","volume":"26","author":"L Goyal","year":"2020","unstructured":"Goyal L et al (2020) Phase I and Biomarker Study of the wnt pathway modulator DKN-01 in combination with Gemcitabine\/Cisplatin in advanced biliary Tract Cancer. Clin Cancer Res 26:6158\u20136167. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1310","journal-title":"Clin Cancer Res"},{"key":"4942_CR115","doi-asserted-by":"publisher","first-page":"S1120","DOI":"10.1016\/j.annonc.2022.07.1371","volume":"33","author":"FS Turkes","year":"2022","unstructured":"Turkes FS et al (2022) 1253P safety and efficacy of wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: phase IIa results of the WAKING trial. Ann Oncol 33:S1120\u2013S1121. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1371","journal-title":"Ann Oncol"},{"key":"4942_CR116","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0959-8049(16)32668-5","volume":"69","author":"J Bendell","year":"2016","unstructured":"Bendell J et al (2016) Initial results from a phase 1a\/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). Eur J Cancer 69:29\u2013S30. https:\/\/doi.org\/10.1016\/S0959-8049(16)32668-5","journal-title":"Eur J Cancer"},{"key":"4942_CR117","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2023.41.16_suppl.2601","volume":"41","author":"DSP Tan","year":"2023","unstructured":"Tan DSP et al (2023) A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours. J Clin Oncol 41:2601\u20132601. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2601","journal-title":"J Clin Oncol"},{"key":"4942_CR118","doi-asserted-by":"publisher","unstructured":"Teneggi V et al (2016) 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours. Annals of Oncology 27, ix47 https:\/\/doi.org\/10.1016\/S0923-7534(21)00310-0","DOI":"10.1016\/S0923-7534(21)00310-0"},{"key":"4942_CR119","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/leu.2017.87","volume":"31","author":"H Zhou","year":"2017","unstructured":"Zhou H et al (2017) Combined inhibition of \u03b2-catenin and bcr-abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 31:2065\u20132074. https:\/\/doi.org\/10.1038\/leu.2017.87","journal-title":"Leukemia"},{"key":"4942_CR120","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3892\/ijo.2016.3360","volume":"48","author":"X Wu","year":"2016","unstructured":"Wu X, Luo F, Li J, Zhong X, Liu K (2016) Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the wnt signaling pathway. Int J Oncol 48:1333\u20131340. https:\/\/doi.org\/10.3892\/ijo.2016.3360","journal-title":"Int J Oncol"},{"key":"4942_CR121","doi-asserted-by":"publisher","first-page":"503084","DOI":"10.1016\/j.mrgentox.2019.503084","volume":"846","author":"S Roy","year":"2019","unstructured":"Roy S et al (2019) Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells. Mutat Res Genet Toxicol Environ Mutagen 846:503084. https:\/\/doi.org\/10.1016\/j.mrgentox.2019.503084","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"4942_CR122","doi-asserted-by":"publisher","first-page":"CT514","DOI":"10.1158\/1538-7445.Am2022-ct514","volume":"82","author":"E \u00c9lez","year":"2022","unstructured":"\u00c9lez E et al (2022) Abstract CT514: a phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5\/6 inhibitor, BI 905677, in patients with advanced solid tumors. Cancer Res 82:CT514\u2013CT514. https:\/\/doi.org\/10.1158\/1538-7445.Am2022-ct514","journal-title":"Cancer Res"},{"key":"4942_CR123","doi-asserted-by":"publisher","first-page":"266","DOI":"10.12659\/msm.901667","volume":"23","author":"C Zhang","year":"2017","unstructured":"Zhang C, Zhang Z, Zhang S, Wang W, Hu P (2017) Targeting of Wnt\/\u03b2-Catenin by Anthelmintic Drug Pyrvinium enhances sensitivity of Ovarian Cancer cells to Chemotherapy. Med Sci Monit 23:266\u2013275. https:\/\/doi.org\/10.12659\/msm.901667","journal-title":"Med Sci Monit"},{"key":"4942_CR124","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.gendis.2022.07.011","volume":"10","author":"R Vlashi","year":"2023","unstructured":"Vlashi R, Zhang X, Wu M, Chen G (2023) Wnt signaling: essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders. Genes Dis 10:1291\u20131317. https:\/\/doi.org\/10.1016\/j.gendis.2022.07.011","journal-title":"Genes Dis"},{"key":"4942_CR125","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X (2020) Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol 13:165. https:\/\/doi.org\/10.1186\/s13045-020-00990-3","journal-title":"J Hematol Oncol"},{"key":"4942_CR126","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4233","volume":"13","author":"M Kahn","year":"2014","unstructured":"Kahn M (2014) Can we safely target the WNT pathway? Nat Rev Drug Discov 13:513\u2013532. https:\/\/doi.org\/10.1038\/nrd4233","journal-title":"Nat Rev Drug Discov"},{"key":"4942_CR127","doi-asserted-by":"publisher","unstructured":"de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Pr\u00e9vostel C (2024) Why is Wnt\/\u03b2-Catenin not yet targeted in Routine Cancer Care? Pharmaceuticals (Basel) 17. https:\/\/doi.org\/10.3390\/ph17070949","DOI":"10.3390\/ph17070949"},{"key":"4942_CR128","doi-asserted-by":"publisher","first-page":"TPS3175","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3175","volume":"42","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos KP et al (2024) A first-in-human, phase 1\/2 trial of FOG-001, a \u03b2-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. J Clin Oncol 42:TPS3175\u2013TPS3175. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS3175","journal-title":"J Clin Oncol"},{"key":"4942_CR129","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR et al (2018) Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol 135:757\u2013777. https:\/\/doi.org\/10.1007\/s00401-018-1830-2","journal-title":"Acta Neuropathol"},{"key":"4942_CR130","doi-asserted-by":"publisher","first-page":"e12795","DOI":"10.1111\/nan.12795","volume":"48","author":"H Zhang","year":"2022","unstructured":"Zhang H et al (2022) CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK\/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis. Neuropathol Appl Neurobiol 48:e12795. https:\/\/doi.org\/10.1111\/nan.12795","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4942_CR131","doi-asserted-by":"publisher","first-page":"e28753","DOI":"10.1002\/pbc.28753","volume":"68","author":"K Patel","year":"2021","unstructured":"Patel K et al (2021) Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma. Pediatr Blood Cancer 68:e28753. https:\/\/doi.org\/10.1002\/pbc.28753","journal-title":"Pediatr Blood Cancer"},{"key":"4942_CR132","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB et al (2024) The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 30:207\u2013217. https:\/\/doi.org\/10.1038\/s41591-023-02668-y","journal-title":"Nat Med"},{"key":"4942_CR133","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jnen\/nlx061","volume":"76","author":"AM Donson","year":"2017","unstructured":"Donson AM et al (2017) Molecular analyses reveal inflammatory mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. J Neuropathol Exp Neurol 76:779\u2013788. https:\/\/doi.org\/10.1093\/jnen\/nlx061","journal-title":"J Neuropathol Exp Neurol"},{"key":"4942_CR134","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.3892\/mmr.2017.6538","volume":"15","author":"J Zhou","year":"2017","unstructured":"Zhou J, Zhang C, Pan J, Chen L, Qi ST (2017) Interleukin\u20136 induces an epithelial\u2013mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. Mol Med Rep 15:4123\u20134131. https:\/\/doi.org\/10.3892\/mmr.2017.6538","journal-title":"Mol Med Rep"},{"key":"4942_CR135","first-page":"505","volume":"14","author":"M Mori","year":"2004","unstructured":"Mori M, Takeshima H, Kuratsu J (2004) Expression of interleukin-6 in human craniopharyngiomas: a possible inducer of tumor-associated inflammation. Int J Mol Med 14:505\u2013509","journal-title":"Int J Mol Med"},{"key":"4942_CR136","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3389\/fonc.2019.00791","volume":"9","author":"S Grob","year":"2019","unstructured":"Grob S et al (2019) Targeting IL-6 is a potential treatment for primary cystic Craniopharyngioma. Front Oncol 9:791. https:\/\/doi.org\/10.3389\/fonc.2019.00791","journal-title":"Front Oncol"},{"key":"4942_CR137","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy S et al (2024) Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol 26:458\u2013472. https:\/\/doi.org\/10.1093\/neuonc\/noad205","journal-title":"Neuro Oncol"},{"key":"4942_CR138","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbrc.2019.04.142","volume":"514","author":"C Chen","year":"2019","unstructured":"Chen C et al (2019) Frequent B7-H3 overexpression in craniopharyngioma. Biochem Biophys Res Commun 514:379\u2013385. https:\/\/doi.org\/10.1016\/j.bbrc.2019.04.142","journal-title":"Biochem Biophys Res Commun"},{"key":"4942_CR139","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.Ccr-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede A et al (2024) TROP2 is Associated with Primary Resistance to Immune Checkpoint Inhibition in patients with Advanced Non-small Cell Lung Cancer. Clin Cancer Res 30:779\u2013785. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2566","journal-title":"Clin Cancer Res"},{"key":"4942_CR140","doi-asserted-by":"publisher","first-page":"200762","DOI":"10.1016\/j.omton.2024.200762","volume":"32","author":"Q Liao","year":"2024","unstructured":"Liao Q et al (2024) TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs. Mol Therapy: Oncol 32:200762. https:\/\/doi.org\/10.1016\/j.omton.2024.200762","journal-title":"Mol Therapy: Oncol"},{"key":"4942_CR141","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s10072-013-1326-8","volume":"34","author":"S Ning","year":"2013","unstructured":"Ning S et al (2013) TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci 34:1745\u20131750. https:\/\/doi.org\/10.1007\/s10072-013-1326-8","journal-title":"Neurol Sci"},{"key":"4942_CR142","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM (2018) The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 9:28989\u201329006. https:\/\/doi.org\/10.18632\/oncotarget.25615","journal-title":"Oncotarget"},{"key":"4942_CR143","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/cmar.S147033","volume":"9","author":"P Xu","year":"2017","unstructured":"Xu P et al (2017) Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas. Cancer Manag Res 9:821\u2013837. https:\/\/doi.org\/10.2147\/cmar.S147033","journal-title":"Cancer Manag Res"},{"key":"4942_CR144","doi-asserted-by":"publisher","first-page":"33658","DOI":"10.1038\/srep33658","volume":"6","author":"P Zeng","year":"2016","unstructured":"Zeng P et al (2016) Impact of TROP2 expression on prognosis in solid tumors: a systematic review and Meta-analysis. Sci Rep 6:33658. https:\/\/doi.org\/10.1038\/srep33658","journal-title":"Sci Rep"},{"key":"4942_CR145","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A et al (2021) Sacituzumab Govitecan in Metastatic Triple-negative breast Cancer. N Engl J Med 384:1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"4942_CR146","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/jco.23.01720","volume":"42","author":"DP Petrylak","year":"2024","unstructured":"Petrylak DP et al (2024) TROPHY-U-01 cohort 2: a phase II study of Sacituzumab Govitecan in Cisplatin-Ineligible patients with metastatic Urothelial Cancer Progressing after previous checkpoint inhibitor therapy. J Clin Oncol 42:3410\u20133420. https:\/\/doi.org\/10.1200\/jco.23.01720","journal-title":"J Clin Oncol"},{"key":"4942_CR147","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s0140-6736(23)01245-x","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402:1423\u20131433. https:\/\/doi.org\/10.1016\/s0140-6736(23)01245-x","journal-title":"Lancet"},{"key":"4942_CR148","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU et al (2024) Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun 15:6707. https:\/\/doi.org\/10.1038\/s41467-024-50558-9","journal-title":"Nat Commun"},{"key":"4942_CR149","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1078-0432.Ccr-16-3107","volume":"23","author":"M Altan","year":"2017","unstructured":"Altan M et al (2017) B7-H3 expression in NSCLC and its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin Cancer Res 23:5202\u20135209. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3107","journal-title":"Clin Cancer Res"},{"key":"4942_CR150","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12013-021-00975-0","volume":"79","author":"X Hu","year":"2021","unstructured":"Hu X, Xu M, Hu Y, Li N, Zhou L (2021) B7-H3, negatively regulated by miR-128, promotes Colorectal Cancer Cell Proliferation and Migration. Cell Biochem Biophys 79:397\u2013405. https:\/\/doi.org\/10.1007\/s12013-021-00975-0","journal-title":"Cell Biochem Biophys"},{"key":"4942_CR151","doi-asserted-by":"publisher","unstructured":"Joshi V et al (2024) B7-H3 expression in breast Cancer and brain metastasis. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25073976","DOI":"10.3390\/ijms25073976"},{"key":"4942_CR152","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C et al (2023) B7-H3 as a therapeutic target in advanced prostate Cancer. Eur Urol 83:224\u2013238. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.004","journal-title":"Eur Urol"},{"key":"4942_CR153","doi-asserted-by":"publisher","first-page":"e70689","DOI":"10.1371\/journal.pone.0070689","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang L et al (2013) B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE 8:e70689. https:\/\/doi.org\/10.1371\/journal.pone.0070689","journal-title":"PLoS ONE"},{"key":"4942_CR154","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.2147\/ott.S201121","volume":"12","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhou C, Zhang D, Huang Z, Zhang G (2019) The anti-apoptotic effect on cancer-associated fibroblasts of B7-H3 molecule enhancing the cell invasion and metastasis in renal cancer. Onco Targets Ther 12:4119\u20134127. https:\/\/doi.org\/10.2147\/ott.S201121","journal-title":"Onco Targets Ther"},{"key":"4942_CR155","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12894-022-01044-1","volume":"22","author":"AM Mahmoud","year":"2022","unstructured":"Mahmoud AM et al (2022) Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. BMC Urol 22:90. https:\/\/doi.org\/10.1186\/s12894-022-01044-1","journal-title":"BMC Urol"},{"key":"4942_CR156","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","volume":"53","author":"A Gregorio","year":"2008","unstructured":"Gregorio A et al (2008) Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology 53:73\u201380. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03070.x","journal-title":"Histopathology"},{"key":"4942_CR157","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","volume":"24","author":"MM Lynch","year":"2024","unstructured":"Lynch MM et al (2024) B7-H3 is widely expressed in soft tissue sarcomas. BMC Cancer 24:1336. https:\/\/doi.org\/10.1186\/s12885-024-13061-4","journal-title":"BMC Cancer"},{"key":"4942_CR158","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40478-021-01167-w","volume":"9","author":"M Digregorio","year":"2021","unstructured":"Digregorio M et al (2021) The expression of B7-H3 isoforms in newly diagnosed glioblastoma and recurrence and their functional role. Acta Neuropathol Commun 9:59. https:\/\/doi.org\/10.1186\/s40478-021-01167-w","journal-title":"Acta Neuropathol Commun"},{"key":"4942_CR159","doi-asserted-by":"publisher","first-page":"e1461304","DOI":"10.1080\/2162402x.2018.1461304","volume":"7","author":"C Zhang","year":"2018","unstructured":"Zhang C et al (2018) Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. Oncoimmunology 7:e1461304. https:\/\/doi.org\/10.1080\/2162402x.2018.1461304","journal-title":"Oncoimmunology"},{"key":"4942_CR160","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","volume":"111","author":"Z Zhou","year":"2013","unstructured":"Zhou Z et al (2013) B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol 111:257\u2013264. https:\/\/doi.org\/10.1007\/s11060-012-1021-2","journal-title":"J Neurooncol"},{"key":"4942_CR161","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath J et al (2020) Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med 26:712\u2013719. https:\/\/doi.org\/10.1038\/s41591-020-0821-8","journal-title":"Nat Med"},{"key":"4942_CR162","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12094-021-02762-y","volume":"24","author":"S Li","year":"2022","unstructured":"Li S et al (2022) Pediatric medulloblastoma express immune checkpoint B7-H3. Clin Transl Oncol 24:1204\u20131208. https:\/\/doi.org\/10.1007\/s12094-021-02762-y","journal-title":"Clin Transl Oncol"},{"key":"4942_CR163","doi-asserted-by":"publisher","unstructured":"Brignole C et al (2023) Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2023-007174","DOI":"10.1136\/jitc-2023-007174"},{"key":"4942_CR164","doi-asserted-by":"publisher","unstructured":"Tang M et al (2022) Evaluation of B7-H3 targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma. Biomolecules 12. https:\/\/doi.org\/10.3390\/biom12121744","DOI":"10.3390\/biom12121744"},{"key":"4942_CR165","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","volume":"29","author":"E Shenderov","year":"2023","unstructured":"Shenderov E et al (2023) Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med 29:888\u2013897. https:\/\/doi.org\/10.1038\/s41591-023-02284-w","journal-title":"Nat Med"},{"key":"4942_CR166","doi-asserted-by":"publisher","unstructured":"Aggarwal C et al (2022) Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2021-004424","DOI":"10.1136\/jitc-2021-004424"},{"key":"4942_CR167","doi-asserted-by":"publisher","first-page":"S657","DOI":"10.1016\/j.annonc.2021.08.1133","volume":"32","author":"E Shenderov","year":"2021","unstructured":"Shenderov E et al (2021) 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion. Ann Oncol 32:S657\u2013S659","journal-title":"Ann Oncol"},{"key":"4942_CR168","doi-asserted-by":"publisher","first-page":"TPS8126","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8126","volume":"42","author":"TK Owonikoko","year":"2024","unstructured":"Owonikoko TK et al (2024) IDeate-Lung02: a phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician\u2019s choice (TPC) in relapsed small cell lung cancer (SCLC). J Clin Oncol 42:TPS8126\u2013TPS8126. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS8126","journal-title":"J Clin Oncol"},{"key":"4942_CR169","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1200\/JCO.2022.40.6_suppl.087","volume":"40","author":"MR Patel","year":"2022","unstructured":"Patel MR et al (2022) DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1\/2 multicenter study. J Clin Oncol 40:87\u201387. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.087","journal-title":"J Clin Oncol"},{"key":"4942_CR170","doi-asserted-by":"publisher","first-page":"11507","DOI":"10.1200\/JCO.2024.42.16_suppl.11507","volume":"42","author":"L Xie","year":"2024","unstructured":"Xie L et al (2024) ARTEMIS-002: phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. J Clin Oncol 42:11507\u201311507. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.11507","journal-title":"J Clin Oncol"},{"key":"4942_CR171","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/jipo-23-18","volume":"7","author":"K Feustel","year":"2024","unstructured":"Feustel K, Martin J, Falchook GS (2024) B7-H3 inhibitors in Oncology clinical trials: a review. J Immunother Precis Oncol 7:53\u201366. https:\/\/doi.org\/10.36401\/jipo-23-18","journal-title":"J Immunother Precis Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04942-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T10:57:54Z","timestamp":1743850674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":171,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4942"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04942-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Unrelated to this work, PKB has consulted for ElevateBio, Genentech, Angiochem, Tesaro, Axiom Healthcare Strategies, InCephalo Therapeutics, Medscape, MPM Capital Advisors, Dantari Pharmaceuticals, SK Life Sciences, Pfizer, CraniUS, Kazia, Sintetica, Voyager Therapeutics, Advise Connect Inspire and Atavistik, and has received research support (institution) from Merck, Mirati, Eli Lilly and Kinnate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}